The GLP-1 Bridge Nobody Wanted to Underwrite: Why Medicare's $50 Copay Is a Fiscal Event, Not a Pharma One
Medicare will cover GLP-1s for obesity from July 1. Private insurers refused the BALANCE risk and CMS took it on alone. The biotechs got the easy read. The fiscal arithmetic is the harder one.
The headline coming out of last Wednesday’s Centers for Medicare & Medicaid Services announcement was that Medicare will, for the first time in its sixty-year history, cover obesity drugs. Beginning July 1, eligible Part D beneficiaries with a body mass index of 35 or greater — or 27 with a qualifying condition — will be able to obtain Wegovy, Zepbound (in the KwikPen formulation) and Eli Lilly’s newly-launched Foundayo for a flat $50 monthly copay. The program, branded the Medicare GLP-1 Bridge, runs through December 31, 2027. The biotech indices read the press release as an unambiguous win for Lilly and Novo Nordisk and bid the equities accordingly. We think the equity market got the trade right and the political market got it wrong. The Bridge is not a coverage decision. It is the first explicit admission that the private insurance industry will not absorb the cost of obesity care, and that the federal government has agreed, by default, to take that liability onto its balance sheet for now.
The mechanics matter here, because they tell you most of what is interesting about the policy choice. The original CMS design, a five-year voluntary demonstration called BALANCE, was supposed to launch January 1, 2027 with Part D plans signing up to cover GLP-1s for obesity at a negotiated $245 net price per monthly supply, in exchange for standardised coverage rules and out-of-pocket caps. The deadline for plan sponsors to commit passed in mid-April. Industry participation fell well short of the 80% threshold CMS had set. UnitedHealth agreed to participate; CVS Health declined. KFF, which has tracked the design from the start, captured the underlying arithmetic with unusual directness in its April 23 analysis: even at the $245 net price, “savings to plans from a lower price may have been insufficient to offset higher costs associated with an uptake in GLP-1 use for obesity treatment.” The Medicare drug pricing think tank concluded plainly that the BALANCE math did not work for insurers. The Bridge is what CMS does instead.
The cost-bearer in the Bridge is the federal government. Humana sits as the central processor handling prior authorisations and reimbursing pharmacies at the $245 net price; CMS pays Humana, beneficiaries pay $50. None of those dollars flow through Part D’s normal risk-bearing mechanics, the $50 copay does not count toward the Part D out-of-pocket cap, and the manufacturer rebates flow back to CMS rather than to plans. KFF’s previous estimate of the ten-year cost of Medicare obesity coverage, $25 billion to $35 billion, is now a federal liability rather than a shared one, and CMS has declined to disclose its updated projection. Bloomberg reported on April 21 that UnitedHealth itself sees “challenges” with the program design. The fiscal consequence is not theoretical. It is happening on July 1.
The CEO commentary
The two pharma chief executives who matter most have spoken on the record about what this means for their businesses. Dave Ricks of Eli Lilly was characteristically direct on CNBC in late January.
Lilly expects Medicare coverage “immediately after the launch” of its oral weight-loss therapy orforglipron, with roughly 20 to 30 million Medicare beneficiaries living with obesity and related conditions potentially eligible — “a significant multiplier on the eligible population.” — David Ricks, Eli Lilly CEO, CNBC interview, January 30, 2026
Ricks’ framing is the bull case as the industry sees it: every Medicare patient who can now access a $50 copay for a drug that previously cost them out of pocket is incremental volume, and the eligible Medicare cohort is, on Lilly’s own number, larger than the entire current paying population for these therapies. Lars Fruergaard Jørgensen of Novo Nordisk, speaking in February ahead of the Medicare price negotiation framework, gave Wall Street the cleanest single sentence on the economics of these drugs as they exist today.
“On average, we provide around 70% in rebates” on US GLP-1 sales. “From a list price of $1,349 for Wegovy, Novo Nordisk ultimately receives only $404.70.” — Lars Fruergaard Jørgensen, Novo Nordisk CEO, February 2025
That gap between list price and realised price is the negotiating room. The Bridge program at $245 net is a roughly 40% step down from Wegovy’s normal realised price as Jørgensen described it, and a roughly 80% step down from list. The manufacturers have accepted that economics for the duration of the Bridge in exchange for the volume curve Ricks is laying out. Both companies will report meaningfully higher US GLP-1 unit volumes over the back half of 2026 and through 2027. Lilly raised its 2026 adjusted earnings guidance to $35.50–$37.00 per share earlier this month and projected revenue between $82 billion and $85 billion on continued GLP-1 strength.
The fiscal arithmetic the market is not pricing
Goldman Sachs’ April 2024 GLP-1 market report, which has aged unusually well, gave the cleanest articulation of the cost ceiling. Jonathan Gruber, the MIT economics professor who helped design both the Massachusetts and the federal health insurance frameworks, was uncharacteristically blunt in that report.
“If 40% of all Americans with obesity took these drugs at current prices — roughly $15,000 per year per person — the bill would total over $1 trillion annually… That is almost as much as the government spends on the entire Medicare program.” — Jonathan Gruber, MIT, in Goldman Sachs Top of Mind, April 2024
Gruber’s number was a ceiling case at list price, and the Bridge runs at the rebated price, but the directional point survives. Chris Shibutani, Goldman’s US biopharmaceuticals analyst, modelled in the same report that Medicare coverage of GLP-1s for obesity had a 50% probability by 2030. With the Bridge, that probability is now effectively 100% for an 18-month window. The question is what happens at the end of 2027, and the answer is that CMS still does not have a financially sustainable design for BALANCE. KFF’s April 23 framing was that “a financially sustainable solution for how to cover GLP-1 drugs for obesity remains elusive,” and the agency has been candid that the Bridge extension to December 2027 is, in part, to buy time to find one.
The Trump administration’s broader pharmaceutical-pricing apparatus — seventeen Most-Favored-Nation agreements now in place covering 86% of branded sales, plus the TrumpRx direct-to-patient platform — provides the political cover. But the MFN agreements with Lilly and Novo Nordisk pre-date the Bridge, and the deals signed last November already locked in price concessions. The Bridge is incremental cost. CMS has not disclosed its updated projection because the answer is uncomfortable to publish in an election cycle.
Our view
The pharmaceutical equities have priced the Bridge as a clean win, and as a volume story over the next eighteen months they are right. Lilly and Novo Nordisk both walk into the back half of 2026 with a paying Medicare cohort they did not have on May 5, on terms manufacturers can model precisely. We do not contest that trade and we do not see a quick way to fade it.
The trade we think is mispriced sits in three other places. First, the long-duration fiscal cost of GLP-1 coverage is now sitting on the federal balance sheet rather than the Part D plan balance sheet, and the next iteration in 2028 will require either a higher-friction design, a sharper price cut, or a structurally larger federal liability. Sovereign credit spreads will not move on a Medicare line item in 2026, but the demographic mathematics of obesity coverage now compounds with the demographic mathematics of Medicare itself, and the long end of the curve will eventually price it. Second, the BALANCE refusal is a signal about US managed care that has been read narrowly when it should be read broadly: the largest private payers calculated that even at $245 the volume curve would destroy their underwriting, which is a statement about benefit design and about the moral hazard embedded in modern obesity care. UnitedHealth’s ambivalence and CVS’s refusal are early indicators that managed care’s margin structure is more fragile than the equities suggest. Third, the orforglipron oral pill, on Lilly’s pipeline and approaching the Medicare-Part-D coverage they are targeting, has the potential to reset the entire delivery economics; the option value sits with the manufacturer with the cleanest oral story, and not yet with the manufacturer with the largest installed injectable base.
The biotechs got the easy read. The fiscal arithmetic is the harder one. The Bridge buys Washington eighteen months to find an architecture for obesity coverage that the insurance industry will participate in. On the current data, there isn’t one.
This note is for information and discussion only and does not constitute investment advice or an offer to buy or sell any security. Quotes are sourced from public statements; positions and views are the author’s and may change without notice.
